WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (the "Company") (Nasdaq:NURO), an innovative health
care company that develops wearable medical technology and point-of-care
diagnostics that help patients and physicians better manage chronic
pain, nerve disorders, and associated sleep disturbances, today reported
first shipments of the second generation of its wearable therapeutic
technology, the SENSUS™ Pain Management System.
SENSUS technology utilizes comfortable, non-invasive electrical nerve
stimulation of sensory nerves to induce a safe and effective elevation
in the level of naturally occurring neuromodulatory chemicals, called
enkephalins, which block the transmission of pain signals throughout the
nervous system. As a result, many patients experience fast-acting,
non-narcotic relief from chronic pain when using SENSUS.
SENSUS is a transcutaneous electrical nerve stimulator with broad
regulatory indications for management of chronic pain and is the only
such device cleared by the FDA specifically for use during sleep. The
device is lightweight and can be worn during the day while remaining
active, and at night while sleeping. It incorporates a tri-axial MEMS
accelerometer that monitors patient body position and movement enabling
automatic regulation of therapeutic parameters.
The device is designed for people with diabetes that suffer from chronic
pain. The most common cause of such pain is painful diabetic neuropathy
(PDN), which affects up to 5 million people in the U.S. alone.
Additional forms of chronic pain that may benefit from transcutaneous
electrical nerve stimulation include fibromyalgia, post herpetic
neuropathy (shingles), and conditions with both chronic pain and
disturbed sleep such as restless leg syndrome.
The second-generation SENSUS builds on the successful launch of the
technology in early 2013. Over 2000 first generation devices have
shipped since launch. The second-generation device is about 20% thinner
and has several key hardware improvements. The thinner design makes the
device more discreet when worn under clothing and more comfortable
during sleep.
"The launch of our second generation SENSUS device demonstrates our
scientific capabilities in wearable medical technology and commitment to
continual innovation. Feedback from patients and physicians on the over
2000 first generation devices in use has been positive and provided us
with a road-map for further improvements, many of which are incorporated
into the second generation device," said Shai N. Gozani, M.D., Ph.D.,
President and Chief Executive Officer of NeuroMetrix. "In addition to
the use of SENSUS in managing chronic pain, the novel integration of
electrical stimulation and activity tracking through the embedded
accelerometer offers exciting opportunities to develop wearable
therapeutic devices for a variety of medical conditions."
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care diagnostics that help patients and
physicians better manage chronic pain, nerve disorders, and associated
sleep disturbances. The Company has a major focus on diabetic
neuropathies, which affect over 50% of people with diabetes. If left
untreated, diabetic neuropathies trigger foot ulcers that may require
amputation and cause disabling chronic pain. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company markets the SENSUS™ Pain Management System for
treating chronic pain, focusing on physicians managing patients with
painful diabetic neuropathy and other forms of chronic pain such as
fibromyalgia, post herpetic neuropathy (shingles), and conditions with
both chronic pain and disturbed sleep such as restless leg syndrome. The
company also markets the DPNCheck® device, which is a rapid,
accurate, and quantitative point-of-care test for peripheral
neuropathies such as diabetic neuropathy. This product is used to detect
neuropathies at an early stage and to guide treatment. For more
information, please visit http://www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
